A2AAR agonist mediated an inhibition of IL-1β and IL-6 in ERA (62% and 66%, respectively) or in RA patients (64% and 67%, respectively) in comparison with control subjects (Figure 3C). This evidence concerns the gene IL6 and rheumatoid arthritis.